Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06963476 · ClinicalTrials.gov registry record · NA

rTMS as Add on Treatment for Substance Use Disorders

A NA study of Alcohol Use Disorder and Opioid Use, sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
1
Study location

NCT06963476: Recruiting NA study of Alcohol Use Disorder and Opioid Use, sponsored by Yale University.

NCT06963476 is a NA study of Alcohol Use Disorder and Opioid Use that is actively recruiting participants, run by Yale University. The registered enrollment target is 80 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06963476, a NA study of Alcohol Use Disorder and Opioid Use, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

This pilot study is designed to test feasibility and superiority of rTMS types and target locations for the optimal rTMS intervention for individuals seeking treatment for Alcohol Use Disorder (AUD) or Opioid Use Disorder (OUD). The critical questions this study seeks to answer are: which rTMS type applied to l-dlPFC in OUD participants will induce the greatest reduction of opioid use post-treatment? Is inhibitory rTMS applied to medial prefrontal cortex (mPFC) more effective than excitatory rTMS applied to l-dlPFC at reducing alcohol use post treatment in AUD participants?

Primary Outcome

Successful completion of the study is defined as completing the rTMS protocol and the 4-week post-treatment follow-up.

Interventions

  • DEVICE repetitive transcranial magnetic stimulation (rTMS) for AUD
  • DEVICE repetitive transcranial magnetic stimulation (rTMS) for OUD

Study Locations (1)

Connecticut

  • Hartford Healthcare - Hartford

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2025-05-12
Est. Completion 2026-05
Phase NA
Yale University

1,492 total trials

What NCT06963476 shows while recruiting

NCT06963476 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (76% lower).

The record links to 2 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which repetitive transcranial magnetic stimulation (rTMS) for AUD is the first listed.

NCT06963476 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT06963476 about?

NCT06963476 is a clinical study titled "rTMS as Add on Treatment for Substance Use Disorders". This pilot study is designed to test feasibility and superiority of rTMS types and target locations for the optimal rTMS intervention for individuals seeking treatment for Alcohol Use Disorder (AUD) or Opioid Use Disorder (OUD). The critical questions this study seeks to answer are: which rTMS type...

What is the current status of trial NCT06963476?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2025-05-12. Estimated completion is 2026-05.

What conditions does trial NCT06963476 study?

This clinical trial studies the following conditions: Alcohol Use Disorder, Opioid Use.

What interventions are being tested in trial NCT06963476?

The interventions under investigation include: repetitive transcranial magnetic stimulation (rTMS) for AUD (DEVICE), repetitive transcranial magnetic stimulation (rTMS) for OUD (DEVICE).

Who is sponsoring clinical trial NCT06963476?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06963476 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06963476's enrollment target sits among peer trials

80 100th of 184 higher than 79 of 184 other Alcohol Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06963476, the US trial registry maintained by the National Library of Medicine. NCT06963476 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.